[IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B].
OBJECTIVE
To observe the therapeutic efficacy of IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.


METHODS
Forty patients ongoing treatment with lamivudine were randomized to three groups: group A, 14 patients with addition of IFN alpha-2b 3MU to ongoing lamivudine, daily, one month, followed by the same dose given every other day, five months; group B, 15 patients with addition of injectable oxymatrine 60 mg daily, three months, followed by oral oxymatrine every day, three months, and group C, 11 patients ongoing treatment with lamivudine alone. The HBV DNA level in serum, HBeAg seroconversion, and ALT level were detected at the end of the treatment.


RESULTS
After 6 months of treatment, HBV DNA became negative in 35.73% patients treated with combination with IFN, and in 13.3% patients treated with combination with oxymatrine. ALT level was normal in 85.71% or 86.66% of patients, respectively. In none of the patients under ongoing treatment with lamivudine alone HBV DNA or HBeAg became negative, and ALT level was normal in 36.36% of patients.


CONCLUSIONS
These data indicated that IFN or oxymatrine in combination with ongoing lamivudine therapy provided effective antiviral therapy in patients with lamivudine-resistant HBV. The addition of IFN or oxymatrine to ongoing lamivudine therapy in lamivudine-resistant patients led to significant inhibition of viral replication and improvement in liver function after 6 months of therapy.
Zhao
Ping
P
The No.302 Hospital of PLA, Beijing 100039, China.
Li
Han-wei
HW
Lou
Min
M
Cheng
Yong-qian
YQ
Lan
Yun
Y
Fu
Jun-liang
JL
D000328:Adult; D000470:Alkaloids / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011807:Quinolizines; D011994:Recombinant Proteins; D016896:Treatment Outcome; D000093842:Matrines
D000470:Alkaloids; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D019259:Lamivudine; D011807:Quinolizines; D011994:Recombinant Proteins; C037573:oxymatrine; D000093842:Matrines